Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
Purpose. Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2017/7432739 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566836037681152 |
|---|---|
| author | Juliana Wons Magdalena A. Wirth Nicole Graf Matthias D. Becker Stephan Michels |
| author_facet | Juliana Wons Magdalena A. Wirth Nicole Graf Matthias D. Becker Stephan Michels |
| author_sort | Juliana Wons |
| collection | DOAJ |
| description | Purpose. Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab to patients who were switched to aflibercept. Methods. A retrospective analysis with 96 eyes switched to aflibercept was conducted. The progression rate of RPE loss was evaluated in patients who showed atrophy one year prior to switch (n=17) or on switch date (n=19). The RPE loss was evaluated by spectral domain optical coherence tomography (SD-OCT). Further, 22 eyes from patients treated with ranibizumab were compared. Results. The median yearly progression of RPE loss after square root transformation showed no significant difference in the year prior to switch compared to the year after switch (p=0.854). In patients who received only ranibizumab, the median yearly progression of RPE loss was 0.15 mm/y, for aflibercept patients, 0.13 mm/y. This difference was not statistically significant (p=0.172). Conclusions. There seems to be a linear progression rate of RPE loss in patients treated with ranibizumab as well as in patients with aflibercept. No significant increase of progression rate was found after switch to aflibercept. |
| format | Article |
| id | doaj-art-83e7ab661b984b38bca9b44603212686 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-83e7ab661b984b38bca9b446032126862025-02-03T01:02:58ZengWileyJournal of Ophthalmology2090-004X2090-00582017-01-01201710.1155/2017/74327397432739Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and AfliberceptJuliana Wons0Magdalena A. Wirth1Nicole Graf2Matthias D. Becker3Stephan Michels4City Hospital Triemli, Zurich, SwitzerlandCity Hospital Triemli, Zurich, SwitzerlandGraf Biostatistics, Winterthur, SwitzerlandCity Hospital Triemli, Zurich, SwitzerlandCity Hospital Triemli, Zurich, SwitzerlandPurpose. Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab to patients who were switched to aflibercept. Methods. A retrospective analysis with 96 eyes switched to aflibercept was conducted. The progression rate of RPE loss was evaluated in patients who showed atrophy one year prior to switch (n=17) or on switch date (n=19). The RPE loss was evaluated by spectral domain optical coherence tomography (SD-OCT). Further, 22 eyes from patients treated with ranibizumab were compared. Results. The median yearly progression of RPE loss after square root transformation showed no significant difference in the year prior to switch compared to the year after switch (p=0.854). In patients who received only ranibizumab, the median yearly progression of RPE loss was 0.15 mm/y, for aflibercept patients, 0.13 mm/y. This difference was not statistically significant (p=0.172). Conclusions. There seems to be a linear progression rate of RPE loss in patients treated with ranibizumab as well as in patients with aflibercept. No significant increase of progression rate was found after switch to aflibercept.http://dx.doi.org/10.1155/2017/7432739 |
| spellingShingle | Juliana Wons Magdalena A. Wirth Nicole Graf Matthias D. Becker Stephan Michels Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept Journal of Ophthalmology |
| title | Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept |
| title_full | Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept |
| title_fullStr | Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept |
| title_full_unstemmed | Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept |
| title_short | Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept |
| title_sort | comparison of progression rate of retinal pigment epithelium loss in patients with neovascular age related macular degeneration treated with ranibizumab and aflibercept |
| url | http://dx.doi.org/10.1155/2017/7432739 |
| work_keys_str_mv | AT julianawons comparisonofprogressionrateofretinalpigmentepitheliumlossinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumabandaflibercept AT magdalenaawirth comparisonofprogressionrateofretinalpigmentepitheliumlossinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumabandaflibercept AT nicolegraf comparisonofprogressionrateofretinalpigmentepitheliumlossinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumabandaflibercept AT matthiasdbecker comparisonofprogressionrateofretinalpigmentepitheliumlossinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumabandaflibercept AT stephanmichels comparisonofprogressionrateofretinalpigmentepitheliumlossinpatientswithneovascularagerelatedmaculardegenerationtreatedwithranibizumabandaflibercept |